文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺20次大分割放疗直肠壁剂量体积目标的细化与验证

Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-01-31

本研究在293例接受20次中度大分割放疗的前列腺癌患者中验证并细化直肠壁剂量体积目标,终点为2级及以上晚期直肠出血。分析发现调强技术下直肠壁接受40 Gy以上剂量的体积百分比影响递增,最终推荐V32≤50%、V50≤25.8%、V60≤10%。

要点

  • 20次大分割放疗后直肠壁剂量体积目标:V32≤50%、V50≤25.8%、V60≤10%。
  • 293例中35例(12%)出现2级及以上晚期直肠出血。
  • 调强技术下直肠壁高剂量体积与晚期直肠出血关联更显著。

核心结论

  • 推荐20次中度大分割放疗的直肠壁剂量体积目标为V32≤50%、V50≤25.8%、V60≤10%,以降低晚期直肠出血风险。

研究设计与样本

  • 单中心回顾性研究,纳入所有接受20次中度大分割放疗的局限期前列腺癌患者,共293例,分析直肠壁相对剂量体积直方图。

主要发现

  • 293例患者中35例(12%)发生2级及以上晚期直肠出血。
  • 单因素分析中抗血栓药物使用、技术(3DCRT vs IMRT/VMAT)及多个直肠壁剂量体积切点与晚期直肠出血显著相关。
  • 3DCRT亚组(N=106)双变量模型未发现独立剂量学预测因子。
  • 调强亚组(N=187)中直肠壁接受40 Gy以上剂量的体积百分比影响 progressively 增高。
  • 基于该模型确认V32、细化V60并新识别V50切点。

关键数值与推荐

  • 直肠壁V32≤50%。
  • 直肠壁V50≤25.8%。
  • 直肠壁V60≤10%。

临床怎么用

  • 制定20次前列腺大分割放疗计划时,应将直肠壁V32控制在50%以内、V50控制在25.8%以内、V60控制在10%以内。
  • 调强技术患者尤需关注直肠壁高剂量体积参数以降低晚期直肠出血风险。

局限性

  • 单中心回顾性研究,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Dose-volume objectives for the rectum have been proposed to limit long term toxicity after moderately hypofractionated radiotherapy (MHRT) for localized prostate cancer. The purpose of the present study is to validate and possibly refine dose volume objective for the rectal wall after 20-fraction MHRT. MATERIALS AND METHODS: All patients treated by 20-fraction MHRT at a single Institution were identified and relative rectal wall (%RW) DVH retrieved. The endpoint of the study is the development of grade 2+ late rectal bleeding (LRB) according to a modified RTOG scale. Clinical and dosimetric predictors of LRB were investigated at both uni- and multi-variable analysis. RESULTS: 293 patients were identified and analyzed. Of them, 35 (12%) developed the endpoint. At univariable analysis, antithrombotic drug usage (yes vs no), technique (3DCRT vs IMRT/VMAT) and several %RW DVH cut-points were significantly correlated with LRB. However, within patients treated by 3DCRT (N = 106), a bi-variable model including anti-thrombotic drug usage and selected %RW dose/volume metrics failed to identify independent dosimetric predictors of LRB. Conversely, within patients treated with intensity modulation (N = 187), the same model showed a progressively higher impact of the percent of RW receiving doses above 40 Gy. Based on this model, we were able to confirm (V32), refine (V60) and identify a novel (V50) cut-point for the %RW. CONCLUSION: We recommend the following dose volume objectives for the %RW in order to minimize the risk of LRB after 20-fraction MHRT: V32 ≤ 50%; V50 ≤ 25.8% and V60 ≤ 10%.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sanguineti G, Faiella A, Farneti A, et al. Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions. Clin Transl Radiat Oncol. 2020. PMID: 32072030. doi:10.1016/j.ctro.2020.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。